| V. Agosto 2024 |
|
Organ System
|
Type
|
Pre-Stage (Non-Cancer)
|
Stage II - III
|
Locally Advanced or Stage IV
|
|
Neoadjuvant
|
Adjuvant
|
≥ 1 st Line Therapy
|
≥ 2 nd Line Therapy
|
| Gastroenterology |
Colorectal Cancer |
|
|
|
|
Beigene LBL-007
(LAG-3 inhibitor)
|
|
|
|
|
Takeda TAK-676:
stimulator of
interferon genes
(STING) agonist
|
|
|
|
|
Pfizer PF- 07329640
LTBR agonist
(Avastin(bevacizumab mAb VEGF-A Sasanlimab PF-06801591 IgG4
|
|
|
|
Pfizer PF-07934040 Pan KRAS inhibitor |
|
|
|
|
Abbvie(LivmoniplimabTGFbeta1/ BudigalimabPD-1 mAb)
|
|
|
|
|
AbbVie Solid Tumors
ABBV-400 (antic-
MET ADC)
|
| GEA/Gastric Cancer |
|
|
|
|
Instit de Recherches Intl Servier (I.R.I.S.) S095029 (anti-NKG2A ) part of combination therapy
|
| Esophageal (SCC) |
|
|
|
|
Abbvie(ABBV-400 Anti c Met)
|
Gastroesophageal
HER2 mutated |
|
|
|
|
Zongertinib (BI 1810631) oral HER2 inhibitor
|
| Gastric |
|
DELFI-L101
>20 pack-years
smoker
(cfDNA)
|
|
|
|
Biliary Tract Cancer
Overexpressed/amplified HER2 |
|
|
|
|
Zongertinib (BI 1810631) oral HER2 inhibitor
|
Biliary Tract or
Gallbladder Cancer
HER2 + |
|
|
|
Zanidatamab (anti-HER2)
|
|
Hepatocellular Carcinoma (HCC)
or Biliary Tract Cancer (BTC) |
|
|
AZ Observational
Durvalumab (blocks PD-L1 binding to both PD-1 and CD80)
|
|
|
| Hepatocelullar |
|
|
|
Genentech Atezolizumab (anti-PD-L1) +/-
Bevacizumab (anti-VEGF)
|
|
|
|
|
BMS (Relativity-106)
(Relatimab, Nivo & Beva)
|
Abbvie(ABBV-400 Anti c Met)
|
|
|
|
GenentechAtezolizumab(antiPD-L1)
AND Bevacizumab (anti-
VEGF) +/-
Tiragolumab (anti-TIGIT)
|
|
| Pancreas |
|
|
|
|
Mirati MRTX849 (Adagrasib): KRAS G12C inhibitor
|
|
|
|
|
Pfizer PF-07934040 (panKRAS inhibitor) |
Cholangiocarcinoma
KRAS mutated |
|
|
|
|
Genfit(GNS561autophagy inhibitor plus Trametinib Mek1/2 inhibitor
|
Cholangiocarcinoma
HER2+ |
|
|
|
Zanidatamab (anti-HER2)
|
|
| Fatty liver disease |
Pre-Cirrhotic MASLD
(MK-6024) Efinopegdutide (peptide and dual agonist at GLP-1) vs Semaglutide
|
|
|
|
|
Pre-Cirrhotic MASLD
(MK-6024) Efinopegdutide (peptide and dual agonist at GLP-1) |
|
|
|
|
| Gynecology |
Breast Cancer |
|
|
|
|
ARV-471 Vepdegestrant (PF-07850327) in combination with Other agents
|
|
|
|
|
ARV-471 Oral PROTAC
|
|
|
|
|
Pfizer VEPDEGESTRANT (ARV 471/PF 07850327), IN COMBINATION WITH PF 07220060
|
Breast Cancer
HER2 mutated |
|
|
|
|
Zongertinib (BI 1810631) oral HER2 inhibitor
|
| Early Stage Breast Cancer |
|
|
Camizestrant
Next Gen SERD
|
|
|
| Endometrial Cancer |
|
|
|
|
MK 2870 (antibody-drug conjugate TROP2)
|
| Ovarian Granulosa |
|
|
|
|
Abbvie(LivmoniplimabTGFbeta1/ BudigalimabPD-1 mAb)
|
| Ovarian Cancer |
|
|
|
|
PF-07820435( Sting Agonist)
|
Uterine and Cervical cancer
Overexpressed/amplified HER2 |
|
|
|
|
Zongertinib (BI 1810631) oral HER2 inhibitor |
| Head and Neck |
HNSCC |
|
|
|
Tisotumab Vedotin (ADC), Pembro,Carboplatin
|
Tisotumab Vedotin (ADC), Pembro,Carboplatin
|
|
|
|
|
PF-07820435(Sting Agonist)
|
|
|
|
|
Takeda Tak 676 Sting agonist
|
|
|
|
|
VM Oncology(VMD 928 TrKA inhibitor
|
|
|
|
|
Abbvie(ABBV-400 Anti c Met)
|
| Pulmonary |
NSCLC: Locally Advanced/Metastatic Nonsquamous NSCLC Harbouring HER2 |
|
|
|
Zongertinib (BI 18106311) HER2- inhibitor vs SOC
|
Zongertinib (BI 1810631) oral HER2 inhibitor |
| NSCLC Advanced Non-Small Cell Lung Cancer |
|
|
|
|
Janssen Lazertinib + Amivantamab
(EGFR and MET
inhibitor)
|
|
|
|
Pfizer PF-07934040 (panKRAS inhibitor) |
|
|
|
|
Pfizer PF- 07329640
LTBR agonist
Bevacizumab(Avastin mAb VEGF-A Sasanlimab PF-06801591 is an IgG4 mAb
|
|
|
|
|
PF-07820435( Sting Agonist)
|
|
|
|
Datopotamab deruxtecan (Dato-DXd) TROP2-directed ADC
|
|
| Non-Small Cell Lung Cancer with KRAS Mutations |
|
|
|
|
RMC-6291 (KRAS ON) & RMC-6236 (PAN KRAS)
|
| LUNG: SSTR+ Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
|
|
|
|
RYZ101 (radiopharmaceutical DOTATATe+Carboplatin+Etopposide+Atezolizumab
|
| Non-Small Cell Lung Cancer with c-Met Mutations |
|
|
|
|
Vebreltinib (APL-101) oral c-Met inhibitor
|
NSCLC
(RET-Mutated) |
|
|
Eli Lilly (Selpercatinib)
|
|
|
| Solid Tumors |
TUMOR AGNOSTIC: ROS1; NTRK1/2/3; ALK; TMD; AKT1/2/3; HER2; MDM-amplified |
|
|
|
|
Hoffman/Roche(entrectinib TKI, alectinib ALK I
|
| SOLID TUMORS: Advanced NSCLC & c-Met Dysregulation |
|
|
|
|
Vebreltinib (APL-101) oral c-Met inhibitor
|
| SOLID TUMORS: c-Met |
|
|
|
|
Abbvie(ABBV-400 Anti c Met versus Lonsurf plus Avastin |
| Advanced Solid tumors G12c |
|
|
|
|
Mirati MRTX849 (Adagrasib): KRAS G12C inhibitor
|
| Overexpressed/amplified/mutated HER2 Solid Tumors |
|
|
|
|
Zongertinib (BI 1810631) oral HER2 inhibitor
|
| Advanced Solid tumors |
|
|
|
|
Takeda Tak 676 Sting agonist
|
|
|
|
|
Abbvie(ABBV-400 Anti c Met)
|
|
|
|
|
Abbvie(Abbv-400 or Abbv0400 plus Bevacizumab or TAS 102 plus Bevacizumab
|
|
|
|
|
PF-07820435( Sting Agonist)
|
|
|
|
|
Pfizer PF- 07329640
LTBR agonist
Bevacizumab(Avastin mAb VEGF-A Sasanlimab PF-06801591 is an IgG4 mAb
|
|
|
|
|
Pfizer PF-07934040 Pan KRAS inhibitor
|
|
|
|
|
Tisotumab Vedotin(ADC ), Pembro,Carboplatin
|
|
|
|
|
MRTX0902 (SOS1 binder that disrupts the SOS1:KRASG12C PPI)
Adagrasib (KRASG12C inhibitor)"
|
|
|
|
|
RMC-6291 (KRAS ON) & RMC-6236 (PAN KRAS)
|
|
|
|
|
Abbvie(LivmoniplimabTGFbeta1/ BudigalimabPD-1 mAb)
|
|
|
|
|
VM Oncology(VMD 928 TrKA inhibitor
|
| Urology |
Urothelial Cel Carcinoma |
|
|
|
|
Pfizer PF- 07329640
LTBR agonist
Bevacizumab(Avastin mAb VEGF-A Sasanlimab PF-06801591 is an IgG4 mAb
|
|
|
|
|
Abbvie(LivmoniplimabTGFbeta1/ BudigalimabPD-1 mAb)
|
|
|
|
|
MerckPembrolizumab PD-1) PLUSVibostolimab (TIGIT) OR Favezelimab (anti-LAG-3
|
|
|
|
|
Zongertinib (BI 1810631) oral HER2 inhibitor |
|
|
|
|
PF-07820435( Sting Agonist)
|
| Renal Cancer |
|
|
|
|
PF-07820435( Sting Agonist)
|
|
DELFI-L101
>20 pack-years
smoker
(cfDNA)
|
|
|
|
| Bladder Cancer |
|
|
|
|
MerckPembrolizumab PD-1) PLUSVibostolimab (TIGIT) OR Favezelimab (anti-LAG-3
|
|
|
|
|
Merck(MK3475-pembrolizumab PD-1 ICI
|
|
DELFI-L101
>20 pack-years
smoker
(cfDNA)
|
|
|
|
| Prostate |
|
|
|
|
Merck(MK5684 (Inhibitor of CYP45011A1)
|
|
|
|
|
Merck(MK5684 (Inhibitor of CYP45011A1)
|
|
|
|
|
Macrogenics(Lorigerlimab(bispecific DART® molecule that targets PD-1 and CTLA-4)
|
|
|
|
|
Lu-TLX591 + SOC (Docetaxel/Abiraterone/Enzultamide/Ga-PSMA-11) vs SOC |
| Dermatology |
Psoriasis |
|
|
|
|
Risankizumab (IL-23 receptor inhibitor antibody)
Deucravacitinib (TYK2 inhibitor)
|
| Melanoma |
|
|
|
|
PF-07820435( Sting Agonist)
|
|
|
|
|
Pfizer PF- 07329640
LTBR agonist
Bevacizumab(Avastin mAb VEGF-A Sasanlimab PF-06801591 is an IgG4 mAb
|
| Skin |
|
DELFI-L101
>20 pack-years
smoker
(cfDNA)
|
|
|
|
| Hematology |
Diffuse Large B-Cell Lymphoma |
|
|
|
Epcoritamab (CD3xCD20 T-cell–engaging, bispecific antibody) in combination with R-CHOP
|
|
| Follicular Lymphoma |
|
|
|
|
Epcoritamab
CD3xCD20 T-cell–engaging, bispecific antibody
|
|
|
|
Epcoritamab with R2 (ER2 ), G/R-CHOP, or G/R-Benda, Rituximab + Lenalidomide (R2)
|
|
| R/R Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma |
|
|
|
|
Epcoritamab
CD3xCD20 T-cell–engaging, bispecific antibody
|
| R/R Marginal Zone Lymphoma or Follicular Lymphoma |
|
|
|
|
Zanubrutinib
(BTK inhibitor)
|
| Lymphoma |
|
|
|
|
VM Oncology(VMD 928 TrKA inhibitor
|
| Agresive B-Cell Lymphoma |
|
|
|
Golcadomide (Cereblon E3 ligase modulator) plus R-CHOP-
|
|
| Waldenström Macroglobulinemia |
|
|
|
BeiGeneb Phase IV Observational Study
(Zanubrutinib)
Tx Naive or R/R
|
|
| Multiple myeloma |
|
|
|
|
Janssen Observational Study
Daratumumab |
|
|
|
CC-92480 (BMS-986348) (cereblon E3 ubiquitin ligase modulating agent)
Carfilzomib (Kyproli)
Dexamethasone
|
|
| Chronic Lymphocytic Leukemia |
|
Venetoclax + Obinutuzumab or Acalabrutinib |
|
Venetoclax + Obinutuzumab or Acalabrutinib |
|
